Last 12 months
Inside the activity.
9 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 1 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 4 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2023 Filed May 16, 2023 22:21 UTC |
Strobeck MatthewDirector
|
GrantCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029932 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,670 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:21 UTC |
Strobeck MatthewDirector
|
GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029932 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,408 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:20 UTC |
Michael Edward L.Director
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029930 · doc4.xml · derivative · entry 4 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:20 UTC |
Michael Edward L.Director
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029930 · doc4.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:20 UTC |
Michael Edward L.Director
|
GrantCommon Stock | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029930 · doc4.xml · nonDerivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,576 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:20 UTC |
Michael Edward L.Director
|
GrantCommon Stock | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029930 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,235 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC |
Iskra Michael S.EVP & CCO
|
Exercise / conversionRestricted Stock Units · Derivative | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 15,825 shares vested on April 1, 2023. F5 · derivative.expiration_date: 15,825 shares vested on April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC |
Iskra Michael S.EVP & CCO
|
Tax withholdingCommon Stock | 6,930 | $89.09 | $617,393.70 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,152 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC |
Iskra Michael S.EVP & CCO
|
GrantCommon Stock | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,082 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. F2 · balance_after: The amount of shares beneficially owned following this transaction include an additional 257 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:16 UTC |
Dilsaver Evelyn SDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 68 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022682 · doc4.xml · derivative · entry 2 Dilsaver Evelyn S · CIK 0001391387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: 68 shares vested on March 31, 2023. F3 · derivative.expiration_date: 68 shares vested on March 31, 2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:16 UTC |
Dilsaver Evelyn SDirector
|
GrantCommon Stock | 68 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022682 · doc4.xml · nonDerivative · entry 1 Dilsaver Evelyn S · CIK 0001391387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:11 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantRestricted Stock Units · Derivative | 31,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021709 · doc4.xml · derivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,028 Underlying: Common Stock · 31,028 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: 10,342 shares will vest on the first anniversary date of the grant date, March 28, 2024; 10,343 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 10,343 shares will vest on the third anniversary date of the grant date, March 28, 2026. F3 · derivative.expiration_date: 10,342 shares will vest on the first anniversary date of the grant date, March 28, 2024; 10,343 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 10,343 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:11 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantNon-Qualified Stock Option · Derivative | 31,027 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021709 · doc4.xml · derivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,027 Underlying: Common Stock · 31,027 shares Expires 2033-03-28 F1 · derivative.exercise_date: 10,342 shares will vest on the first anniversary date of the grant date, March 28, 2024; 10,342 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 10,343 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:12 UTC |
Bujarski Robert JosephEVP & COO
|
GrantRestricted Stock Units · Derivative | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021710 · doc4.xml · derivative · entry 2 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. F1 · derivative.expiration_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:12 UTC |
Bujarski Robert JosephEVP & COO
|
GrantNon-Qualified Stock Option · Derivative | 14,775 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021710 · doc4.xml · derivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires 2033-03-28 F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:12 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021711 · doc4.xml · derivative · entry 2 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. F1 · derivative.expiration_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:12 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantNon-Qualified Stock Option · Derivative | 14,775 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021711 · doc4.xml · derivative · entry 1 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires 2033-03-28 F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:14 UTC |
Kroll WernerSVP, Research & Development
|
GrantRestricted Stock Units · Derivative | 11,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021715 · doc4.xml · derivative · entry 1 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,433 Underlying: Common Stock · 11,433 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 3,811 shares will vest on the first anniversary date of the grant date, March 28, 2024; 3,811 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 3,811 shares will vest on the third anniversary date of the grant date, March 28, 2026. F2 · derivative.expiration_date: 3,811 shares will vest on the first anniversary date of the grant date, March 28, 2024; 3,811 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 3,811 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC |
Hodges Michelle ASVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 7,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021712 · doc4.xml · derivative · entry 2 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,388 Underlying: Common Stock · 7,388 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: 2,462 shares will vest on the first anniversary date of the grant date, March 28, 2024; 2,463 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 2,463 shares will vest on the third anniversary date of the grant date, March 28, 2026. F3 · derivative.expiration_date: 2,462 shares will vest on the first anniversary date of the grant date, March 28, 2024; 2,463 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 2,463 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC |
Hodges Michelle ASVP, General Counsel
|
GrantNon-Qualified Stock Option · Derivative | 7,386 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021712 · doc4.xml · derivative · entry 1 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,386 Underlying: Common Stock · 7,386 shares Expires 2033-03-28 F1 · derivative.exercise_date: 2,462 shares will vest on the first anniversary date of the grant date, March 28, 2024; 2,462 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 2,462 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC |
Iskra Michael S.EVP & CCO
|
GrantRestricted Stock Units · Derivative | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021713 · doc4.xml · derivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. F1 · derivative.expiration_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC |
Iskra Michael S.EVP & CCO
|
GrantNon-Qualified Stock Option · Derivative | 14,775 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021713 · doc4.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires 2033-03-28 F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantRestricted Stock Units (Premium) · Derivative | 3,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014632 · doc4.xml · derivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,273 Underlying: Common Stock · 3,273 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on February 28, 2024. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on February 28, 2024. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantRestricted Stock Units (Converted) · Derivative | 10,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014632 · doc4.xml · derivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,656 Underlying: Common Stock · 10,656 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units vested on February 28, 2023. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.expiration_date: The restricted stock units vested on February 28, 2023. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Tax withholdingCommon Stock | 7,527 | $88.71 | $667,720.17 |
DisclosureSEC source: 0001209191-23-013176 · doc4.xml · nonDerivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,543 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of performance-based restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantCommon Stock | 15,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013176 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,070 F1 · shares: Reporting Person acquired these shares in connection with full achievement of performance metrics associated with performance-based restricted stock units awarded on February 3, 2020. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:15 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionNon-Qualified Stock Options · Derivative | 8,081 | $0.00 Strike: $23.70 | $0.00 |
DisclosureSEC source: 0001209191-23-011625 · doc4.xml · derivative · entry 3 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,081 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vested in full. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:15 UTC |
BUECHLER KENNETH FDirector
|
SaleCommon Stock | 8,081 | $90.26 | $729,366.01 |
DisclosureSEC source: 0001209191-23-011625 · doc4.xml · nonDerivative · entry 2 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,288 F1 · price: The weighted average sale price for these transactions was $90.2569 per share, with a range of $90.00 to $90.77. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:15 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionCommon Stock | 8,081 | $23.70 | $191,519.70 |
DisclosureSEC source: 0001209191-23-011625 · doc4.xml · nonDerivative · entry 1 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · derivative · entry 6 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 7,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · derivative · entry 5 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Tax withholdingCommon Stock | 1,087 | $86.50 | $94,025.50 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · nonDerivative · entry 4 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 526,890 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantCommon Stock | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · nonDerivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,977 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Tax withholdingCommon Stock | 3,453 | $86.50 | $298,684.50 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · nonDerivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,785 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantCommon Stock | 7,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009166 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,238 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 824 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · derivative · entry 6 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 2,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · derivative · entry 5 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
Tax withholdingCommon Stock | 434 | $86.50 | $37,541.00 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · nonDerivative · entry 4 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,112 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
GrantCommon Stock | 824 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · nonDerivative · entry 3 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,546 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
Tax withholdingCommon Stock | 1,381 | $86.50 | $119,456.50 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · nonDerivative · entry 2 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,722 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:45 UTC |
Bujarski Robert JosephEVP & COO
|
GrantCommon Stock | 2,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009167 · doc4.xml · nonDerivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,103 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 823 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · derivative · entry 6 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 823 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 2,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · derivative · entry 5 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,743 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
Tax withholdingCommon Stock | 409 | $86.50 | $35,378.50 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · nonDerivative · entry 4 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,255 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
GrantCommon Stock | 823 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · nonDerivative · entry 3 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,664 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
Tax withholdingCommon Stock | 1,296 | $86.50 | $112,104.00 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · nonDerivative · entry 2 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,841 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 16:46 UTC |
Kroll WernerSVP, Research & Development
|
GrantCommon Stock | 2,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009170 · doc4.xml · nonDerivative · entry 1 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,137 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 18,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007502 · doc4.xml · derivative · entry 6 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,720 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 18,720 shares vested on February 4, 2023. F5 · derivative.expiration_date: 18,720 shares vested on February 4, 2023. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
Tax withholdingCommon Stock | 9,282 | $89.70 | $832,595.40 |
DisclosureSEC source: 0001209191-23-007502 · doc4.xml · nonDerivative · entry 4 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,929 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 16:15 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantCommon Stock | 18,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007502 · doc4.xml · nonDerivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,211 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.